Advertisement

Rate of Progression of Parkinson’s Disease in Early and Late Prescription of Levodopa

  • A. V. RosinskayaEmail author
  • E. E. Vasenina
  • T. N. Khaybullin
  • O. S. Levin
Article
  • 3 Downloads

Objectives. To optimize levodopa treatment depending on the rate of disease progression. Materials and methods. A total of 86 patients with Parkinson’s disease were studied. The rate of progression was evaluated in terms of the time taken to reach stage 3. Assessment of patients’ status was based on the MDS-UPDRS, MMSE, Beck Depression Scale, scales for apathy and autonomic impairments, tests for verbal activity, and the clock drawing test. Results and conclusions. Earlier initiation of levodopa treatment in 37 patients (mean 1.7 years from onset of PD) led to the appearance of signs of reaching disease stage 3 later than those given levodopa later (mean 7.3 ± 4.4 years vs. 5.8 ± 2.8 years). The development of dyskinesias occurred at the same times in patients with early initiation of levodopa as in those with later initiation (7.5 years vs. 7.9 years from onset of PD). Retention of asymmetry in clinical manifestations during the course of disease, REM sleep behavior disorder, and orthostatic hypotension were predictors of a high risk of complications of levodopa. More severe axial impairments predicted faster progression, low levodopa efficacy, and a lower risk of dyskinesia. Thus, delayed initiation of levodopa was linked with faster progression, while the development of therapeutic dyskinesia depended more on the duration of disease than the time at which levodopa treatment was initiated.

Keywords

Parkinson’s disease levodopa rate of progression predictors of complications 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    O. S. Levin and N. V. Fedorova, Parkinson’s Disease, MedPress-Inform (2016), 5th ed.Google Scholar
  2. 2.
    S. H. Fox, R. Katzenschlager, S. Lim, et al., “International Parkinson and Movement Disorder Society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease,” Mov. Disord. (2018), Epub ahead of print,  https://doi.org/10.1002/mds.27372.
  3. 3.
    P. J. Garcia-Ruiz, J. C. Martinez Castrillo, and A. Alonso-Canovas, “Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study,” J Neurol. Neurosurg. Psychiatry, 85, 840–844 (2014),  https://doi.org/10.1136/jnnp-2013-306787.CrossRefGoogle Scholar
  4. 4.
    P. Worth, “Results of the early stage PD MED study: revelation or recapitulation?” Pract. Neurol., 15, 408–410 (2015),  https://doi.org/10.1136/practneurol-2015-001149.CrossRefGoogle Scholar
  5. 5.
    N. Tambasco, M. Romoli, and P. Calabresi, “Levodopa in Parkinson’s disease: current status and future developments,” Curr. Neuropharmacol., Epub ahead of print,  https://doi.org/10.2174/1570159X15666170510143821.
  6. 6.
    M. Hoehn and M. Yahr, “Parkinsonism: onset, progression and mortality,” Neurology, 17, No. 5, 427–442 (1967),  https://doi.org/10.1212/wnl.17.5.427.
  7. 7.
    Y. J. Zhao, H. L. Wee, Y. H. Chan, et al., “Progression of Parkinson’s disease as evaluated by Hoehn and Yahr stage transition times,” Mov. Disord., 25, No. 6, 710–716 (2010),  https://doi.org/10.1002/mds.22875.CrossRefGoogle Scholar
  8. 8.
    C. G. Goetz, S. Fahn, P. Martinez-Martin, et al., “Movement Disorder Society-sponsored revision of the Unifi ed Parkinson’s Disease Rating Scale (MDS-UPDRS, Process, format, and clinimetric testing plan,” Mov. Disord., 22, No. 1, 41–47 (2007),  https://doi.org/10.1002/mds.21198.
  9. 9.
    C. McRae, G. Diem, A. Vo, et al., “Schwab and England: Standardization of administration,” Mov. Disord., 15, 335–336 (2000),  https://doi.org/10.1002/1531-8257(200003)15:2<335::AIDMDS1022>3.0.CO;2-V.CrossRefGoogle Scholar
  10. 10.
    Cognitive assessment, the Folstein Mini-Mental State Examination (MMSE). Clinical Skills for OSCEs (2006), 2nd ed., https://doi. org/10.1201/b17661-53.Google Scholar
  11. 11.
    P. Manos, “The ten-point clock test: a quick screen for cognitive impairment in medical and surgical patients,” Am. J. Clin. Geriatr. Psychiatry, 7, 49 (1994),  https://doi.org/10.1097/00019442-199911001-00142.
  12. 12.
    J. M. Glozman, “Quantitative and qualitative integration of Lurian procedures,” Neuropsychol. Rev., 9, 23 (1999),  https://doi.org/10.1023/A:1025638903874.CrossRefGoogle Scholar
  13. 13.
    C. Beck and R. Gable, “Postpartum Depression Screening Scale: development and psychometric testing,” Nursing Res., 49, No. 5, 272–282 (2000),  https://doi.org/10.1097/00006199-200009000-00006.CrossRefGoogle Scholar
  14. 14.
    S. Starkstein, “Apathy in Parkinson’s disease: Diagnostic and etiological dilemmas,” Mov. Disord., 27, No. 2, 174–178 (2012),  https://doi.org/10.1002/mds.24061.CrossRefGoogle Scholar
  15. 15.
    A. J. Espay and A. E. Lang, “Common myths in the use of levodopa in Parkinson Disease: when clinical trials misinform clinical practice,” JAMA Neurol., 74, No. 6, 633–634 (2017),  https://doi.org/10.1001/jamaneurol.2017.0348.CrossRefGoogle Scholar
  16. 16.
    Parkinson Study Group, “A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD study,” Clin. Neuropharmacol., 23, No. 1, 34–44 (2000),  https://doi.org/10.1097/00002826-200001000-00007.
  17. 17.
    A. Whone, R. Watts, A. Stoessl, et al., “Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study,” Ann. Neurol., 54, No. 1, 93–101 (2003),  https://doi.org/10.1002/ana.10609.CrossRefGoogle Scholar
  18. 18.
    J. Zhang and L. C. Tan, “Revisiting the medical management of Parkinson’s disease: levodopa versus dopamine agonist,” Curr. Neuropharmacol., 14, No. 4, 356–363 (2016),  https://doi.org/10.2174/1570159X14666151208114634.CrossRefGoogle Scholar
  19. 19.
    G. Mostile, A. Nicoletti, V. Dibilio, et al., “Switching L-dopa therapy from pulsatile to pulse administration reduces motor complications in Parkinson’s disease,” Eur. J. Neurol., 21, No. 1, 104–387 (2014),  https://doi.org/10.1097/wnf.0000000000000186.Google Scholar
  20. 20.
    A. Antonini, V. Fung, J. Boyd, et al., “Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson’s disease patients,” Mov. Disord., 31, No. 4, 530–537 (2016),  https://doi.org/10.1002/mds.26528.CrossRefGoogle Scholar
  21. 21.
    C. C. Aquino and S. H. Fox, “Clinical spectrum of levodopa-induced complications,” Mov. Disord., 30, 80–89 (2015),  https://doi.org/10.1002/mds.26125.CrossRefGoogle Scholar
  22. 22.
    Z. Yao, Y. Shao, and X. Han, “Freezing of gait is associated with cognitive impairment in patients with Parkinson disease,” Neurosci. Lett., 656, 126–130 (2017),  https://doi.org/10.1016/j.neulet.2017.07.004.CrossRefGoogle Scholar
  23. 23.
    D. S. Peterson, L. A. King, R. G. Cohen, and F. B. Horak, “Cognitive contributions to freezing of gait in Parkinson disease: implications for physical rehabilitation,” Phys. Ther., 96, No. 5, 659–670 (2016),  https://doi.org/10.2522/ptj.20140603.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • A. V. Rosinskaya
    • 1
    • 2
    Email author
  • E. E. Vasenina
    • 2
  • T. N. Khaybullin
    • 3
  • O. S. Levin
    • 2
  1. 1.Primorye Regional Clinical Hospital No. 2VladivostokRussia
  2. 2.Russian Medical Academy for Continuing Professional EducationRussian Ministry of HealthMoscowRussia
  3. 3.Semey City State Medical UniversitySemeyKazakhstan

Personalised recommendations